Literature DB >> 22317848

A dosimetric evaluation of dose escalation for the radical treatment of locally advanced vulvar cancer by intensity-modulated radiation therapy.

Monique C W M Bloemers1, Lorraine Portelance, Russell Ruo, William Parker, Luis Souhami.   

Abstract

The purpose of this planning study was to determine whether intensity-modulated radiation therapy (IMRT) reduces the radiation dose to organs at risk (OAR) when compared with 3D conventional radiation therapy (3D-CRT) in patients with vulvar cancer treated by irradiation. This study also investigated the use of sequential IMRT boost (seq-IMRT) and simultaneous integrated boost (SIB-IMRT) for dose escalation in the treatment of locally advanced vulvar cancer. Five vulvar cancer patients treated in the postoperative setting and 5 patients treated with definitive intent (def-group) were evaluated. For the postoperative group, 3D-CRT and IMRT plans to a total dose (TD) of 45 Gy were generated. For the def-group, 4 plans were generated: a 3D-CRT and an IMRT plan to a TD of 56.4 Gy, a SIB-IMRT plan to a TD of 56 Gy, and a SIB-IMRT with dose escalation (SIB-IMRT-esc): TD of 67.2 Gy. Mean dose and dose-volume histograms were compared using Student's t-test. IMRT significantly (all p < 0.05) reduced the D(mean), V30, and V40 for all OAR in the adjuvant setting. The V45 was also significantly reduced for all OAR except the bladder. For patients treated in the def-group, all IMRT techniques significantly reduced the D(mean), V40, and V45 for all OAR. The mean femur doses with SIB-IMRT and SIB-IMRT-esc were 47% and 49% lower compared with 3D-CRT. SIB-IMRT-esc reduced the doses to the OAR compared with seq-3D-CRT but increased the D(max.) for the small bowel, rectum, and bladder. IMRT reduces the dose to the OAR compared with 3D-CRT in patients with vulvar cancer receiving irradiation to a volume covering the vulvar region and nodal areas without compromising the dosimetric coverage of the target volume. IMRT for vulvar cancer is feasible and an attractive option for dose escalation studies.
Copyright © 2012 American Association of Medical Dosimetrists. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22317848     DOI: 10.1016/j.meddos.2011.11.005

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  4 in total

Review 1.  "Unresectable" vulval cancers: is neoadjuvant chemotherapy the way forward?

Authors:  Kathryn Graham; Kevin Burton
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

2.  Intensity modulated radiation therapy for squamous cell carcinoma of the vulva: Treatment technique and outcomes.

Authors:  Yuan James Rao; Anupama Chundury; Julie K Schwarz; Comron Hassanzadeh; Todd DeWees; Daniel Mullen; Matthew A Powell; David G Mutch; Perry W Grigsby
Journal:  Adv Radiat Oncol       Date:  2017-02-28

3.  Conventional radiotherapy and intensity-modulated radiotherapy in carcinoma vulva: An experience from a tertiary medical center of India.

Authors:  Koustav Mazumder; Arun Elangovan; Bhavana Rai; Vanita Suri; Vanita Jain; Jaswinder Kalra; Sushmita Ghoshal
Journal:  South Asian J Cancer       Date:  2019 Jan-Mar

4.  Simultaneously integrated boost (SIB) spares OAR and reduces treatment time in locally advanced cervical cancer.

Authors:  Christine H Feng; Yasmin Hasan; Malgorzata Kopec; Hania A Al-Hallaq
Journal:  J Appl Clin Med Phys       Date:  2016-09-08       Impact factor: 2.102

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.